United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 4 minute read Pharma Industry News Abpro and Celltrion reveal promising preclinical results for ABP-102/CT-P72 at AACR 2025 Discover how Abpro and Celltrion’s ABP-102/CT-P72 could reshape HER2 cancer treatment with promising preclinical results. Read the full details now! byPallavi MadhirajuApril 28, 2025